Wikipedia -WSS

Wikipedia

author：explore 2025-10-01 23:57:12 - browse：7

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： What don’t we know about an Alzheimer’s drug side effect?

WSS

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

The Affordable Care Act has saved billions in health care costs

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Biogen walks away from Aduhelm, years after polarizing approval

Medicare drug price negotiation legal challenge met with skepticism

Investment in vaccine development is lagging, report finds

hotspot

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

The EPA's new lead rule: How one expert crunched the numbers

How one medical school became remarkably diverse

U.K. Biobank has 500,000 peoples' genome sequences available

In age of alternative facts, a scholarly course on calling out crap

Organ aging and disease risk measured by new blood test

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Boston competes with Raleigh

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Vertex non

leisure time

Medicare Advantage insurers face 0.2% cut to 2025 payments

Readout Newsletter: The latest on Novavax, Merck, Bluebird

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

With clinical trial data readouts, here's how to spot spin

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Flagship Pioneering launches a new biotech in two countries

knowledge

knowledge

explore

hotspot